Nektar Therapeutics - NKTR
About Gravity Analytica
Recent News
- 09.18.2025 - Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
- 09.18.2025 - Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
- 09.15.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
- 09.15.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
- 09.10.2025 - H.C. Wainwright 27th Annual Global Investment Conference
- 09.10.2025 - H.C. Wainwright 27th Annual Global Investment Conference
- 09.09.2025 - Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
- 09.09.2025 - Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
- 09.03.2025 - Nektar Therapeutics to Participate in Two Investor Conferences in September
Recent Filings
- 09.18.2025 - EX-99.1 EX-99.1
- 09.18.2025 - 8-K Current report
- 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
- 09.09.2025 - 144 Report of proposed sale of securities
- 09.08.2025 - 4 Statement of changes in beneficial ownership of securities
- 09.08.2025 - 4 Statement of changes in beneficial ownership of securities
- 09.05.2025 - 144 Report of proposed sale of securities
- 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
- 09.04.2025 - 144 Report of proposed sale of securities
- 09.04.2025 - 4 Statement of changes in beneficial ownership of securities